Otros idiomas Immunovia AB

Acciones

IMMNOV

SE0006091997

Equipo médico y tecnología avanzada

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 18:00:00 06/03/2026			Variación 5 días	Varia. 1 de enero.
0,1712 ^SEK	-0,81 %		-21,29 %	-24,58 %

03/03	Two Sigma Investments se convierte en nuevo vendedor en corto público en Immunovia	FW
24/02	Immunovia AB, Q4 2025 Earnings Call, Feb 24, 2026

Otros idiomas

25/02	Research update Immunovia Q4 2025: Targeting Medicare sub-mission by mid-2026
24/02	Immunovia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
24/02	Immunovia Q4 oper loss SEK 16.7 mln
24/02	Immunovia Publishes Full Year Report for 2025
24/02	Certain Shares of Immunovia AB are subject to a Lock-Up Agreement Ending on 24-FEB-2026.
23/02	Immunovia : Invitation to presentation of Immunovia's Q4 2025 report
23/02	Invitation to presentation of Immunovia’s Q4 2025 report
23/01	Immunovia attends Aktiespararna Life Science
20/01	Immunovia board withdraws reverse share split proposal, cancels meeting
20/01	The Board of Directors of Immunovia withdraws proposal for reverse share split and cancels Extraordinary General Meeting
19/01	Global markets live: General Motors, Tesla, Micron, KKR, Bayer…
19/01	Immunovia AB Receives State Regulatory Approval for Pancreasure in California and Initiates Commercial Rollout
19/01	Immunovia Wins Approval for PancreaSure Test in US
19/01	Immunovia gets state regulatory approval for Pancreasure in California
19/01	Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout
15/01	Immunovia establish the 2026 Nomination Committee
22/12	Immunovia’s Analytical Validation Study of PancreaSure Published in Diagnostics
18/12	Immunovia board proposes reverse share split
17/12	NOTICE OF EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)
17/12	The Board of Directors of Immunovia proposes a reverse share split
28/11	Change in number of shares and votes in Immunovia AB (publ)
27/11	Research update Immunovia, Q3 2025: US reimbursement in focus
26/11	Immunovia receives final Medicare payment rate for Pancreasure test
26/11	Immunovia receives final Medicare payment rate for PancreaSure™ test
26/11	Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025